Результаты поиска

Метод газовой хроматографии для количественного определения остаточных растворителей в наноформуляциях.

Описано разработку и проверку метода газовой хроматографии, который является чувствительным, быстрым и специфичным для оценки 19 распространенных растворителей класса 2 и класса 3, часто используемых в формулировке наномедицины. Проверка метода проводилась с использованием системы газовой хроматографии PerkinElmer с детектированием искровой ионизации и колонки Elite 624 Crossbond 6% цианопропилфенил-94% диметилполисилоксана или DB-Fatwax-Ultra Inert с гелием в качестве носителя. Оценены характеристики валидации, такие как линейность, восстановление при добавлении, точность метода, специфичност

Совпадение в полном тексте источника
… Development and validation of the GC method for the quantitative determination of semi-volatile solvents in the pharmaceutical substance bosentan. Acta Pol. Pharm. Drug Res. 2014;71:1107–1113. 34. Tian J., Chen G., He Z. …

Sclerosing diseases of the skin.

Sclerosing skin diseases comprise a group of distinct dermatological conditions characterized by fibrotic changes that may severely impair patients' quality of life. These conditions often present with cutaneous manifestations and, in some cases, may extend to extracutaneous tissues, potentially resulting in significant morbidity and mortality. This review explores the current understanding of the four most prevalent sclerosing skin diseases - localized scleroderma (morphea), systemic sclerosis (SSc), scleromyxedema, and scleredema adultorum of Buschke - as well as sclerotic conditions induced

Совпадение в полном тексте источника
… Bosentan should be considered to reduce the formation of new ulcers, particularly in patients who experience multiple ulcers despite treatment with calcium channel blockers, PDE‐5 inhibitors, or iloprost. 67 Patients with pulmonary involvement in SSc should be treated rapidly with immunosuppressive …

Diagnostic and management dilemmas in pulmonary hypertension.

INTRODUCTION: Although current international guidelines provide comprehensive evidence-based guidance for the management of pulmonary hypertension, clinicians are still regularly faced with uncertainty regarding correct diagnosis and optimal treatment. METHODS: Ten diagnostic and management dilemmas were formulated by a panel of experts in the field of pulmonary hypertension. Current evidence was reviewed and a practical approach suggested for each dilemma. RESULTS: Diagnostic and management dilemmas discussed include pulmonary hypertension with high cardiac output, idiopathic pulmonary arte

Совпадение в полном тексте источника
… Among endothelin receptor antagonists, bosentan and macitentan were tested in heart failure in the studies BADDHY and MELODY-1, respectively, the latter specifically targeting patients with CpcPH [ 37 , 38 ]. …

Pulmonary Hypertension in an Oncologic Intensive Care Unit

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Other pulmonary vasodilators In the outpatient setting, endothelin receptor agonists (bosentan, ambrisentan, macitentan), phosphodiesterase-5 inhibitors (sildenafil and tadalafil), the soluble guanylate cyclase agonist (riociguat), as well as oral prostanoids (selexipag, Orenitram) are all widely used …

IgA Vasculitis (Henoch-Schönlein Purpura): An Update on Treatment.

Objective: IgA vasculitis (IgAV), previously named as Henoch-Schönlein purpura, is the most frequent systemic vasculitis in children. In adults, IgAV is less common although it is associated with more severe disease. In fact, the frequency of glomerulonephritis (referred to as IgAV nephritis) in adults is higher than in children and tends to present more severely, with around 10-30% of those affected eventually progressing to end-stage renal disease. In this review, we describe the pathophysiology, main clinical features, diagnosis of the disease, and latest clinical data regarding IgAV therap

Совпадение в полном тексте источника
… There are three ETA/ETB receptor antagonists under study in glomerular diseases: sparsentan, atrasentan, and bosentan ( Table 2 ). Sparsentan is a dual endothelin- and angiotensin-receptor antagonist with high selectivity for the ETA receptor and angiotensin II receptor type 1 [ 119 ]. …

Heart failure with preserved ejection fraction in cancer patients and survivors. A scientific statement of the Heart Failure Association of the ESC and the ESC Council of Cardio-Oncology.

Heart failure with preserved ejection fraction (HFpEF) is increasingly recognized in cancer patients and survivors, yet it remains underdiagnosed and its epidemiology largely unknown. This statement underscores the imperative need to include HFpEF in the cardiotoxicities identified during or after anticancer treatments. It also highlights the prognostic value of pre-existing HFpEF for periprocedural and cardiotoxicity risk and it discusses the challenges in the diagnosis and treatment of HFpEF in cancer patients. It also explores the aetiologic role of anticancer therapies (chemotherapy, targe

Совпадение в полном тексте источника
… Improvement of bleomycin‐induced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist bosentan . Respir Physiol Neurobiol 2010 ; 170 : 32 – 36 . 10.1016/j.resp.2009.11.005 19931426 55 National Cancer Institute. …

Chronic Kidney Disease: Strategies to Retard Progression.

Chronic kidney disease (CKD), defined as the presence of irreversible structural or functional kidney damages, increases the risk of poor outcomes due to its association with multiple complications, including altered mineral metabolism, anemia, metabolic acidosis, and increased cardiovascular events. The mainstay of treatments for CKD lies in the prevention of the development and progression of CKD as well as its complications. Due to the heterogeneous origins and the uncertainty in the pathogenesis of CKD, efficacious therapies for CKD remain challenging. In this review, we focus on the follo

Совпадение в полном тексте источника
… Anti-IL-1 monoclonal antibody Signal transduction pathway | Ruboxistaurin | PKCβ inhibitor Selonsertib | ASK1 inhibitor Fasudil | Rho kinase inhibitor Vasoactive agents | Avosentan | ET type A receptor antagonist Atrasentan | ET type A receptor antagonist Sitaxsentan | ET type A receptor antagonist Bosentan …

B-cells in pulmonary arterial hypertension: friend, foe or bystander?

There is an unmet need for new therapeutic strategies that target alternative pathways to improve the prognosis of patients with pulmonary arterial hypertension (PAH). As immunity has been involved in the development and progression of vascular lesions in PAH, we review the potential contribution of B-cells in its pathogenesis and evaluate the relevance of B-cell-targeted therapies. Circulating B-cell homeostasis is altered in PAH patients, with total B-cell lymphopenia, abnormal subset distribution (expansion of naïve and antibody-secreting cells, reduction of memory B-cells) and chronic acti

Совпадение в полном тексте источника
… Anti-ETAR antibodies also increase HUVEC permeability and expression of vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF)-B, as well as human PA-SMC proliferation and expression of PDGF receptor-β; both of which are annulled by exposure to bosentan [ 86 ]. …

Nanomedicine for cancer patient-centered care.

Cancer is a leading cause of morbidity and mortality worldwide, and an increase in incidence is estimated in the next future, due to population aging, which requires the development of highly tolerable and low-toxicity cancer treatment strategies. The use of nanotechnology to tailor treatments according to the genetic and immunophenotypic characteristics of a patient's tumor, and to allow its targeted release, can meet this need, improving the efficacy of treatment and minimizing side effects. Nanomedicine-based approach for the diagnosis and treatment of cancer is a rapidly evolving field. Se

Совпадение в полном тексте источника
… adenocarcinoma, stage IV pancreatic cancer AJCC | Anne Noonan | Phase 2 NCT04137653 | Treatment of triple‐negative breast cancer with albumin‐bound paclitaxel as neoadjuvant therapy: a prospective RCT | Recruiting | Breast cancer | Shengjing Hospital | Phase 3 NCT04158635 | Gemcitabine, Nab‐paclitaxel, and bosentan …

Phosphodiesterase type 5 and cancers: progress and challenges.

Cancers are an extraordinarily heterogeneous collection of diseases with distinct genetic profiles and biological features that directly influence response patterns to various treatment strategies as well as clinical outcomes. Nevertheless, our growing understanding of cancer cell biology and tumor progression is gradually leading towards rational, tailored medical treatments designed to destroy cancer cells by exploiting the unique cellular pathways that distinguish them from normal healthy counterparts. Recently, inhibition of the activity of phosphodiesterase type 5 (PDE5) is emerging as a

Совпадение в полном тексте источника
… Safety and efficacy of combined use of sildenafil, bosentan, and iloprost before and after liver transplantation in severe portopulmonary hypertension. Liver Transpl. 2008;14:287–291. doi: 10.1002/lt.21310. 172. Cadden IS, Greanya ED, Erb SR, Scudamore CH, Yoshida EM. …

A comprehensive review on pain: Model, target, therapy, and prospect (Review).

Pain serves as both a protective physiological response essential for species survival and a global health issue affecting human well‑being and societal development. The present review systematically summarized and analyzed the research progresses on pain through a multidimensional analytical framework encompassing animal models, molecular targets, therapeutic approaches and future prospects. In animal modeling, neuropathic pain paradigms have evolved from traditional mechanical compression to composite models that combine dynamic displacement and chemical stimulation. Cancer‑induced pain mode

Совпадение в полном тексте источника
… The model has validated analgesics (morphine, bosentan and pregabalin) and revealed peripheral endothelin receptor-trigeminal sensitization linkages ( 61 ). …

Haematological Diseases in the Tropics

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… syndrome (different pathophysiology) Mortality risk with even mild pulmonary hypertension is high Regular blood transfusions and long-term anticoagulation have been tried Hydroxycarbamide may decrease the risk Prostacycline analogues (epoprostenol, and iloprost), endothelin-1 receptor antagonists (bosentan …

Abstract

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 31st Европейский педиатрический конгресс по педиатрии: часть 1.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 29th Европейский конгресс педиатрии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Ход работы сессии 28th Европейский конгресс педиатрической ремуматологии (ПСР) 2022) Прага, Чешская Республика. 20-23 сентябрь 2022.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Резюме: 31 Европейский конгресс патологии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.